Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Dna X (SONM) Long-Term Investments (2024 - 2025)

Dna X's Long-Term Investments history spans 2 years, with the latest figure at $12.0 million for Q4 2025.

Quarterly results put Long-Term Investments at $12.0 million for Q4 2025, up 68.85% from a year ago — trailing twelve months through Dec 2025 was $12.0 million (up 68.85% YoY), and the annual figure for FY2025 was $12.0 million, up 68.85%.
Long-Term Investments for Q4 2025 was $12.0 million at Dna X, up from $7.1 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $12.0 million in Q4 2025 to a low of $7.1 million in Q4 2024.